Track topics on Twitter Track topics that are important to you
Pfizer has licensed exclusive global rights to Akcea Therapeutics’ Phase II cardiovascular and metabolic disease candidate AKCEA-ANGPTL3-LRx, through an agreement that could generate up to $1.5 billion-plus for Akcea and its corporate parent Ionis Pharmaceuticals.
The post Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5B appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5BNEXT ARTICLE
Pfizer is a global pharmaceutical company, the largest in world based on annual sales. In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...